The story so far
written Nov 5What is happening
AstraZeneca's reported $10 billion bid for Rhythm Pharmaceuticals would expand its rare-disease portfolio through its Alexion unit 245. The non-binding proposal, reported on November 4, 2026, offers a base price of $124 per share for the rare-obesity drugmaker 3913. The price could reach $134 per share if the company meets specific milestones 359. Rhythm shares rose 28% to $110.68 on November 4, 2026, following reports of the offer 2610.
What to watch
A formal merger agreement between AstraZeneca and Rhythm Pharmaceuticals would establish the timeline for the acquisition. Rhythm Pharmaceuticals shareholders would then need to approve the deal in a formal vote.
Regulatory reviews would follow the signing of a definitive agreement. A ruling from the U.S. Federal Trade Commission and a final decision from the UK Competition and Markets Authority would be required for the deal to proceed. AstraZeneca and Rhythm would announce the closing of the transaction and an integration plan upon receiving these clearances.
Read the full brief · how we got here
How we got here
Rhythm Pharmaceuticals reported $92.1 million in product revenue for the third quarter of 2026 on November 2, 2026 5617. AstraZeneca's offer for the company was reported two days later, on November 4, 2026 4914. AstraZeneca declined to comment on the reports, and Rhythm did not respond to requests for comment 513.
References · 10
- 2marketscreener.com — AstraZeneca made a $10bn offer to buy Rhythm Pharmaceuticals
- 3coinunited.io — AstraZeneca's $10B Rhythm Pharma Bid: Leverage Scenarios, M&A ...
- 4mediabias.news — AstraZeneca bids for Rhythm | MediaBias News
- 5easternherald.com — AstraZeneca’s Reported Rhythm Bid Targets Rare Obesity
- 6biomednexus.com — Rhythm Jumped 28% on a Reported AstraZeneca Takeover Bid
- 9piqmarkets.com — AstraZeneca made about $10 billion offer for Rhythm, sources ...
- 10finance.yahoo.com — Rhythm Pharmaceuticals stock surges 28% on AstraZeneca bid report
- 13reuters.com — AstraZeneca made $10 billion offer for obesity drugmaker ...
- 14wsj.com — AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals
- 17markets.businessinsider.com — Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial ...
What would close this
0 of 4 metTimeline
1newest firstWhen we started following: AstraZeneca makes unconfirmed $10 billion non-binding bid for Rhythm Pharmaceuticals
AstraZeneca submitted a non-binding proposal to acquire Rhythm Pharmaceuticals for approximately $10 billion 49. The offer, reported on November 4, 2026, values the rare-obesity drugmaker at a base price of $124 per share, potentially rising to $134 per share if certain milestones are met 359.
Following reports of the bid, Rhythm shares rose 28% to close at $110.68 on November 4, 2026 246. The acquisition would be managed through AstraZeneca's rare-disease unit, Alexion 245. AstraZeneca declined to comment on the reports, and Rhythm did not respond to requests for comment 5. The offer follows Rhythm's November 2, 2026, third-quarter earnings report, which showed $92.1 million in product revenue 56. No formal merger agreement has been announced 5.